IBM ponders a sale

Article Excerpt

IBM, $122.36, is still a buy. The company (New York symbol IBM; Shares o/s: 893.6 million; Market cap: $107.5 billion; TSINetwork Rating: Above Average; Yield: 5.3%) announced recently that it will spin off its Managed Infrastructure Services unit. That legacy business helps clients manage their datacentres. Now, the company is reportedly considering selling its IBM Watson Health business. That unit helps health-care providers manage data. Its brands include Merge Healthcare, which analyzes mammograms and MRIs; Phytel, which assists with patient communications; and Truven, which analyzes complex healthcare data. IBM paid around $2.6 billion for Truven in 2016, almost $1 billion for Merge Healthcare in 2015 and around $230 million for Phytel. IBM remains a buy. buy…